No Data
Zhejiang Garden Biopharmaceutical (300401.SZ): Zhejiang Garden Pharmaceutical has obtained the pharmaceutical registration certificate for Alendronate Sodium Tablets.
On November 22, Glonghui reported that zhejiang garden biopharmaceutical (300401.SZ) announced that its wholly-owned subsidiary zhejiang garden pharmaceutical co., ltd. (hereinafter referred to as "garden pharmaceutical") recently received the "pharmaceutical registration certificate" for alendronate sodium tablets approved by the National Medical Products Administration. Alendronate sodium tablets are primarily used to treat osteoporosis in postmenopausal women and male osteoporosis to increase bone mass. Alendronate sodium tablets are classified as Category B drugs in the "National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Directory (2023)."
Zhejiang Garden Biopharmaceutical (300401.SZ): The company's convertible bonds vitamin A project has started production.
Zhejiang garden biopharmaceutical (300401.SZ) stated on the investor interaction platform on November 11 that the company's convertible bonds vitamins A project has started production.
Huafu Securities: BASF delays the resumption time of vitamins E and A production, prices are expected to continue to rise.
Due to the explosion, BASF delayed the reproduction time of vitamins E and A. After this news was announced, vitamins E and A quickly stopped falling and rebounded.
Zhejiang Garden Biopharmaceutical (300401.SZ): Vitamins B6 and biotin projects are actively progressing as planned.
On October 21, zhejiang garden biopharmaceutical (300401.SZ) stated on the investor interaction platform that the company's VA project now has production capacity, and vitamins B6 and biotin projects are actively progressing according to plan.
Zhejiang Garden Biopharmaceutical (300401.SZ): The production and sales of vitamin D3 in the third quarter increased both year-on-year and quarter-on-quarter.
Zhejiang Garden Biopharmaceutical (300401.SZ) stated on the investor interaction platform on October 21 that the company's production and sales of vitamin D3 in the third quarter have increased year-on-year and quarter-on-quarter.
Garden Biology: Report for the third quarter of 2024
Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Shares May Have Run Too Fast Too SoonNo Data
No Data
